
|Podcasts|April 26, 2018
Significant Improvement Found in Clinical Trial for Dravet Syndrome
Author(s)Andrew N. Wilner, MD
An expert describes the efficacy of fenfluramine in decreasing seizure frequency associated with this rare syndrome.
Advertisement
Fenfluramine proved successful in decreasing seizure frequency in a Phase 3 study of Dravet syndrome, a rare pediatric condition known for its treatment resistance.
In this podcast, Dr. Wilner interviews Arnold Gammaitoni, PharmD, about this potentially game-changing new epilepsy drug.
If these results can be duplicated, it raises the possibility of a new, effective treatment for seizures in children with Dravet syndrome.
RELATED CONTENT:
More podcasts
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
5-Year Data Support Safety of MRI-Guided AAV2-GDNF Gene Therapy in Advanced Parkinson Disease
2
FDA Grants Fast Track Designation to T-Cell Agent CK0803 for ALS
3
FDA Action Update, Week of August 23, 2026: Authorization, Clinical Hold, and Clearance
4
Top 5 Spinal Muscular Atrophy Headlines of 2026: What Neurologists Should Know
5














